Endovia closes $500K convertible debt financing from C/M Capital for CannEpil development

SPLASH BEVERAGE GROUP, INC.

Closed $500,000 initial secured convertible debt from C/M Capital Master Fund, LP; first tranche of $1M commitment.
Funds support CannEpil® FDA veterinary program (INAD File No. 14145) and international commercialization.
Partner Lupvindol Biosciences Ltd. advancing canine oncology pain program; exclusive global rights from Argent BioPharma.
H.R. 10150 (introduced Aug 27, 2026) proposes 12-year market exclusivity for FDA-approved botanical drugs.
FDA launched initiative on botanical drug development; company cites growing federal support for cannabis-derived therapies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.